Inventor
SUTTON PAUL ALLEN
US17 patents
⚠️ This page may combine multiple inventors who share the name “SUTTON PAUL ALLEN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
NOVARTIS AG
7 patentsUS8580806B2Nov 12, 2013
Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
NOVARTIS AG9 citations83
US8343984B2Jan 1, 2013
Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
NOVARTIS AG11 citations82
US9163005B2Oct 20, 2015
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
NOVARTIS AG6 citations81
US8829015B2Sep 9, 2014
Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
NOVARTIS AG7 citations81
US11786498B2Oct 17, 2023
Sacubitril calcium salts
NOVARTIS AG0 citations56
US7247746B2Jul 24, 2007
Crystal forms of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine
NOVARTIS AG1 citations51
US9334276B2May 10, 2016
Forms and salts of a dihydropyrrolo[1,2c]imidazolyl aldosterone synthase or aromatase inhibitor
NOVARTIS AG0 citations42
MANLEY PAUL W
3 patentsUS8163904B2Apr 24, 2012
Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide
MANLEY PAUL W32 citations94
US8389537B2Mar 5, 2013
Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MANLEY PAUL W17 citations91
US8415363B2Apr 9, 2013
Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide
MANLEY PAUL W15 citations88
FENG LILI
2 patentsUS8877938B2Nov 4, 2014
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
FENG LILI44 citations95
US9388134B2Jul 12, 2016
Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
FENG LILI5 citations81
NOVARTIS PHARMACEUTICALS CORP
2 patentsUS11642329B2May 9, 2023
Amorphous solid form of compounds containing S—N-valeryl-N- {[2′-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
NOVARTIS PHARMACEUTICALS CORP0 citations60
US11096918B2Aug 24, 2021
Amorphous solid form of compounds containing S—N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations
NOVARTIS PHARMACEUTICALS CORP0 citations60